Protagonist Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a discovery through late-stage development biopharmaceutical company utilizing its proprietary technology platform to discover and develop novel peptide-based therapeutics. The company's platform enables the de novo design of targeted peptide drugs that combine the high specificity of antibody therapeutics with the convenience of oral or targeted delivery. Protagonist's strategic focus is centered on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its business model relies on a combination of disciplined internal development and high-value strategic partnerships with global pharmaceutical leaders, notably Johnson & Johnson (Janssen) and Takeda Pharmaceuticals, to scale clinical development and commercialization.
Research as of 29 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Shifting the commercialization strategy of late-stage assets to a high-margin royalty and milestone-driven model by opting out of the 50:50 U.S. profit-and-loss sharing arrangement with Takeda for rusfertide.
Expected impact: Eliminates the need for a costly commercial buildout in hematology, while securing up to $975 million in milestone payments and tiered worldwide royalties ranging from 14% to 29%.
Developing and advancing highly differentiated, fully-owned peptide candidates, specifically PN-881 (oral IL-17 antagonist) and PN-477 (subcutaneous and oral triple GLP/GIP/GICG agonists).
Expected impact: Establishes a proprietary pipeline in inflammatory and obesity-related indications to drive long-term growth independent of current partnerships.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High strategic importance for the global development and commercialization of rusfertide in polycythemia vera.
Terms: Takeda paid a $300 million upfront payment in 2024. Following Protagonist's April 2026 opt-out election, Protagonist is eligible to receive up to $975 million in milestone payments (including a $200 million opt-out fee and a $75 million milestone upon FDA approval) and tiered worldwide royalties ranging from 14% to 29%.
High strategic importance for the development and commercialization of oral IL-23 receptor antagonists, including ICOTYDE (icotrokinra).
Terms: Protagonist received a $50 million milestone payment in Q1 2026 triggered by the FDA approval of ICOTYDE. Protagonist is eligible for up to $580 million in future regulatory and sales milestones, plus tiered global royalties of 6% to 10%.